Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI) (PANDA)
Sponsor: Beijing Anzhen Hospital
This NA trial investigates Aortic Dissection and Cardiovascular Diseases (CVD) and is currently actively recruiting participants. Beijing Anzhen Hospital leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
4 versions recorded-
Dec 2024 — Present [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Not Yet Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting NA
-
Feb 2024 — Jul 2024 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Beijing Anzhen Hospital
- Nanjing Medical University
- The First Affiliated Hospital with Nanjing Medical University
For direct contact, visit the study record on ClinicalTrials.gov .